Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates



VERVE-101 CRISPR gene editing treatment. read more »

Inclisiran (previously ALN-PCSsc)

Phase I study (reformulated) Fitzgerald K, et al. 2014. read more »


LIB003 is a recombinant fusion drug which combines a PCSK9-binding domain (adnectin) with human serum albumin. LIB003 is given as a monthly subcutaneous more »


Alirocumab is being evaluated in the ODYSSEY clinical trial programme including studies in patients with familial hypercholesterolaemia (FH), and patients with hypercholesterolaemia, including those at high cardiovascular more »


Evolocumab has been evaluated in the PROFICIO (Program to Reduce LDL-C and Cardiovascular Outcomes Following Inhibition of PCSK9 In Different Populations) clinical trial more »


Bococizumab: SPIRE clinical trial programme (terminated).read more »